1,130 Shares in Intuitive Surgical, Inc. $ISRG Purchased by My Legacy Advisors LLC

Key Points

• My Legacy Advisors LLC acquired 1,130 shares of Intuitive Surgical, Inc. valued at approximately $594,000 during the 2nd quarter.
• Insider Gary S. Guthart sold 29,360 shares of the company's stock, reducing his ownership by nearly 60%, while another executive, Myriam Curet, sold 4,500 shares, marking a 92.73% decrease in her position.
• Analysts largely favor Intuitive Surgical, with a consensus rating of "Moderate Buy" and a target price averaging $595.95, reflecting confidence despite recent mixed ratings from various analysts.

My Legacy Advisors LLC bought a new stake in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) in the 2nd quarter, according to its most recent disclosure with the SEC. The fund bought 1,130 shares of the medical equipment provider's stock, valued at approximately $594,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Norway Savings Bank grew its position in shares of Intuitive Surgical by 53.4% during the second quarter. Norway Savings Bank now owns 2,613 shares of the medical equipment provider's stock worth $1,420,000 after buying an additional 910 shares in the last quarter. Trust Co. of Oklahoma acquired a new position in shares of Intuitive Surgical during the second quarter worth about $363,000. Neville Rodie & Shaw Inc. grew its position in shares of Intuitive Surgical by 11.9% during the second quarter. Neville Rodie & Shaw Inc. now owns 10,427 shares of the medical equipment provider's stock worth $5,666,000 after buying an additional 1,110 shares in the last quarter. Arlington Trust Co LLC grew its position in shares of Intuitive Surgical by 34.5% during the first quarter. Arlington Trust Co LLC now owns 745 shares of the medical equipment provider's stock worth $369,000 after buying an additional 191 shares in the last quarter. Finally, Mogy Joel R Investment Counsel Inc. grew its position in shares of Intuitive Surgical by 1.2% during the second quarter. Mogy Joel R Investment Counsel Inc. now owns 68,678 shares of the medical equipment provider's stock worth $37,320,000 after buying an additional 840 shares in the last quarter. 83.64% of the stock is owned by institutional investors and hedge funds.

Intuitive Surgical Price Performance

Intuitive Surgical stock traded up $5.02 during trading hours on Tuesday, hitting $449.57. The stock had a trading volume of 855,143 shares, compared to its average volume of 2,042,283. The stock has a market capitalization of $161.16 billion, a price-to-earnings ratio of 62.64, a PEG ratio of 4.60 and a beta of 1.61. Intuitive Surgical, Inc. has a 1-year low of $425.00 and a 1-year high of $616.00. The stock's fifty day moving average is $475.20 and its two-hundred day moving average is $502.92.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last issued its quarterly earnings data on Tuesday, July 22nd. The medical equipment provider reported $2.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.93 by $0.26. Intuitive Surgical had a return on equity of 14.56% and a net margin of 28.51%.The business had revenue of $2.44 billion for the quarter, compared to the consensus estimate of $2.35 billion. During the same period in the prior year, the business earned $1.78 earnings per share. The business's revenue was up 21.4% on a year-over-year basis. As a group, sell-side analysts anticipate that Intuitive Surgical, Inc. will post 6.43 EPS for the current year.

Insider Activity

In other news, Director Amy L. Ladd sold 335 shares of the company's stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $440.69, for a total value of $147,631.15. Following the sale, the director directly owned 739 shares in the company, valued at $325,669.91. This represents a 31.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Gary S. Guthart sold 29,360 shares of the company's stock in a transaction on Friday, August 29th. The shares were sold at an average price of $472.49, for a total value of $13,872,306.40. Following the completion of the sale, the insider owned 19,827 shares in the company, valued at $9,368,059.23. This represents a 59.69% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 45,224 shares of company stock worth $21,716,492 over the last three months. 0.70% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities analysts have recently commented on ISRG shares. UBS Group boosted their price objective on Intuitive Surgical from $547.00 to $585.00 and gave the stock a "neutral" rating in a research report on Wednesday, July 23rd. Truist Financial boosted their target price on Intuitive Surgical from $590.00 to $600.00 and gave the stock a "buy" rating in a research note on Wednesday, July 23rd. Deutsche Bank Aktiengesellschaft restated a "sell" rating on shares of Intuitive Surgical in a research note on Friday, August 22nd. Wall Street Zen upgraded Intuitive Surgical from a "hold" rating to a "buy" rating in a research note on Saturday, July 26th. Finally, Erste Group Bank restated a "hold" rating on shares of Intuitive Surgical in a research note on Wednesday, July 23rd. Thirteen equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $595.95.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.